S1PR2 expression correlates directly with overall survival in DLBCL patients. (A-H) Kaplan–Meier curves displaying overall survival probability of 3 DLBCL patient cohorts (Gene Expression Omnibus accession numbers GSE31312 and GSE10846) treated either with R-CHOP (rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone; A,C,D,F,G) or with CHOP only (B,E,H) as a function of FOXP1 expression (A-C), S1PR2 expression (D-F), and FOXP1/S1PR2 expression combined (G-H). All cohorts were subdivided based on low (<median) or high (>median) FOXP1 expression and low (first to third quartile) and high (fourth quartile) S1PR2 expression. The log-rank test was used for statistical analysis (*P < .05, **P < .01, and ***P < .001). The patient cohorts shown were enrolled in the Lymphoma/Leukemia Molecular Profiling Project (A-B,D-E,G-H) and in the International DLBCL Rituximab-CHOP Consortium Program Study (C,F). n.s., not significant.